Angiotensins in Alzheimer's disease - friend or foe?

Research output: Contribution to journalReview article (Academic Journal)peer-review

154 Citations (Scopus)


The renin-angiotensin system (RAS) is an important regulator of blood pressure. Observational and experimental studies suggest that alterations in blood pressure and components of the brain RAS contribute to the development and progression of Alzheimer's disease (AD), resulting in changes that can lead or contribute to cognitive decline. The complexity of the RAS and diversity of its interactions with neurological processes have recently become apparent but large gaps in our understanding still remain. Modulation of activity of components of the brain RAS offers substantial opportunities for the treatment and prevention of dementia, including AD. This paper reviews molecular, genetic, experimental and clinical data as well as the therapeutic opportunities that relate to the involvement of the RAS in AD.
Translated title of the contributionAngiotensins in Alzheimer's disease - friend or foe?
Original languageEnglish
Pages (from-to)619 - 628
Number of pages10
JournalTrends in Neurosciences
Issue number12
Early online date30 Sept 2009
Publication statusPublished - Dec 2009

Bibliographical note

Publisher: Elsevier


Dive into the research topics of 'Angiotensins in Alzheimer's disease - friend or foe?'. Together they form a unique fingerprint.

Cite this